TrovaGene, Inc. Announces Data Presentations, Published Abstracts At Annual Meeting Of American Society of Clinical Oncology

SAN DIEGO, May 14, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). An additional abstract, submitted by Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer, has been accepted for publication in 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology.

Poster Presentation Details

Title: Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients.
Abstract Number: 127572
Date:Monday, June 2, 2014
Display Time:8 a.m. to 11 a.m. CDT
Display Location: S405
Poster Number: 1

Presentation Time: 11:30 a.m. to 12:45 p.m. CDT
Location: S406
Presentation Order: 3

Published Abstract Details

Title: Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers
Lead Investigator: Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center
Abstract Number: 130132

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA and RNA in urine. The company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.

Contact

Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

SOURCE Trovagene, Inc.